We investigated the relationship between the lipid levels achieved in a high-risk group of patients undergoing primary prevention with pravastatin and the incidence of cardiovascular disease, and moreover the influence of lifestyle compliance on lipid control. Methods: In the APPROACH-J study, 6,229 patients who were treated with pravastatin were enrolled, and will be followed for two years. The subjects are men aged 20 years or older and women aged 55 years or older (or postmenopausal women) receiving primary prevention, who are categorized as high-risk patients with 3 or more major risk factors other than the LDL-C level according to the Japan Atherosclerosis Society guideline. Achieved LDL-C levels will be used to categorize the subjects into four quartiles for this analysis, and the maximum contrast method based on the Cox proportional hazards model will be used to investigate the relations between achieved LDL-C and the incidence of vascular event. Multiple linear regression analysis will be used to investigate the relations between adherence scores and achieved lipid level. Results: In 5,871 patients (58.5% women) who were eligible for analysis, the mean age was 66.4 years. The mean LDL-C at baseline was 135.9 mg/dL. The risk factors other than LDL-C were aging in 95.4%, diabetes in 76.9%, hypertension in 72.2%, a family history of coronary artery disease (CAD) in 20.9%, smoking in 20.0%, and low high-density lipoprotein cholesterol in 11.1%.
Introduction
Lifestyle-related diseases, such as dyslipidemia, hypertension, and diabetes mellitus, are increasing with the Westernization of the lifestyle and the rapid aging of society in Japan, and it is a concern that the incidence of atherosclerotic disease will elevate even CAD. It was also proposed to set the target reduction rate for LDL-C at 20-30% 10) . The MEGA study demonstrated that a significant benefit was obtained by lowering the LDL-C level to approximately 120 mg/dL or by a reduction of 20% in intermediate-risk and high-risk patients undergoing primary prevention, validating the target levels in the JAS guideline. However, sufficient Japanese evidence is not currently available regarding the connection between the risk-related reduction of LDL-C and the decline in the risk of atherosclerotic disease in patients receiving primary prevention, so further studies are needed.
Lifestyle modification is the basis of all approaches to the prevention of atherosclerotic disease, and its significance has been repeatedly emphasized in the JAS guideline, the "Campaign for national health in the 21st century (Healthy Japan 21)", and "Obligations regarding health guidance for patients with metabolic syndrome" released by the Japanese Ministry of Health, Labor and Welfare in 2008. Good adherence to adequate diet therapy, exercise therapy, and drug therapy is important for long-term improvement of lifestyle 11) , but insufficient data regarding the adherence to such treatment are available in Japan.
Therefore, in the present study, we examined the validity of the target LDL-C level in the JAS guideline based on the relationship between lipid control and the incidence of vascular disease in high-risk patients treated with pravastatin for primary prevention, and also investigated the influence of adherence on lipid control.
Methods
The design of the APPROACH-J Study is shown in Fig. 1 . The APPROACH-J study was started in February 2008 with a target of 5,000 patients to be centrally enrolled until January 2009, and the patients to be followed for two years until January 2011. The subjects are men aged 20 years or older and women aged 55 years or older (or postmenopausal women) undergoing primary prevention, who are categorized as high-risk patients with 3 or more major risk factors other than the LDL-C level (gender/aging, hypertension, diabetes mellitus (including impaired glucose tolerance), smoking, a family history of CAD, and low HDL-C) according to the JAS guideline. These major risk factors (Table 2) were reported by the attending physicians. Hypertension and diabetes were diagnosed by the physicians while information on smoking and the family history of CVD was obtained from the patients. Lipid parameters were measured at each hospital or clinic laboratory.
All enrolled patients were starting or continuing treatment with pravastatin and gave written informed consent. The exclusion criteria were: 1) a history of vascular disease (myocardial infarction, unstable angina, revascularization (percutaneous coronary intervention (PCI)/coronary artery bypass graft (CABG)) for CAD, or stroke); 2) serious arrhythmia; 3) familial dyslipidemia; 4) poorly controlled blood pressure or blood glucose; 5) serious hepatic dysfunction or serious renal dysfunction; 6) other serious dis- Vascular events were as follows: fatal/non-fatal myocardial infarction, unstable angina requiring hospitalization, PCI/CABG (including coronary interventions), fatal/non-fatal stroke (except transient ischemic attack (TIA)), arteriosclerosis obliterans, sudden and unexpected death related to cardiovascular disease.
Questionnaire consisted of 21 questions concerning lifestyle to obtain information on lifestyle adherence, interest in health, diet, and exercise (including exercise according to "Exercise and Physical Activity Guide for Health Promotion 2006"), smoking status, and drug therapy (treatment compliance for drugs including pravastatin, and understanding of their drug therapy). eases such as malignant tumors; 7) contraindications to pravastatin therapy; and 8) other reasons judged by the investigator to render the patients inappropriate for long-term administration of pravastatin. At baseline and 1 year after initiation of the study, the subjects completed a questionnaire consisting of 21 questions concerning their lifestyle to obtain information on lifestyle adherence, interest in health, diet, and exercise (including exercise according to "Exercise and Physical Activity Guide for Health Promotion 2006" 12) , smoking status, and drug therapy (treatment compliance for drugs including pravastatin, and understanding of their drug therapy) (Appendix 1).
Follow-up was continued for 24 months after initiation of the study irrespective of whether administration of pravastatin continued, and the investigator contacted subjects who failed to visit the hospital at 12 and 24 months after initiation of the study to confirm their health status. No restrictions were placed on other treatment, and all treatments were recorded. The baseline patient characteristics, including complications and the physician's target LDL-C level, were reported in the clinical report form. Blood pressure, laboratory data, compliance with pravastatin therapy, concomitant medications, and the presence/absence of vascular events at baseline, and after 6, 12, 18, and 24 months were recorded in the clinical report form every year. Adverse events, which were defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment, were investigated throughout the study period. This study was performed in compliance with the Japanese standards for post-marketing surveillance.
The primary composite endpoint was the first occurrence of vascular disease, which included fatal/ non-fatal myocardial infarction, unstable angina requiring hospitalization, PCI/CABG (including coronary interventions), fatal/non-fatal stroke (except transient ischemic attack (TIA)), arteriosclerosis obliterans, and sudden and unexpected death related to cardiovascular disease. The secondary endpoints were as follows: 1) subsets of the primary endpoint, 2) adherence scores obtained from the patient questionnaire, 3) vital signs and laboratory tests, and 4) safety. Vascular events reported by the investigators will be assessed by the Endpoint Committee. The study organization and the members of the Medical Expert Advisory Committee are detailed in Appendix 2.
Sample Size Determination
The incidence of vascular disease in high-risk Japanese patients was estimated at 17/1,000 person years based on the incidence in the Japanese diabetic population 13) . The achieved LDL-C levels were used to categorize the subjects into four quartiles (Q1, Q2, Q3, and Q4 in descending order). When we assumed that the preventive effect on vascular disease peaks at around the target LDL-C level (120-140 mg/dL), the hazard ratios of Q2, Q3, and Q4 versus Q1 were all 0.6 14) . Taking dropouts into account and based on the above assumptions, a sample size of 5,000 subjects would have an 80% probability of detecting the assumed contrast using the maximum contrast method 15) .
Statistical Analysis
The maximum contrast method 15) based on the Cox proportional hazards model will be used to investigate the relations between achieved LDL-C and the incidence of vascular event. Achieved LDL-C levels will be used to categorize the subjects into four quartiles for this analysis. Subgroup analysis will be conducted using pravastatin-naïve patients, and analyses will also be conducted for the LDL-C reduction rate and LDL-C reduction level instead of achieved LDL-C. Multiple linear regression analysis will be used to investigate the relations between adherence scores and achieved LDL-C levels.
Results
The results reported here describe the baseline characteristics of the subjects enrolled in the APPROACH-J study. A total of 6,229 patients were enrolled at 864 Japanese medical institutions. Among them, 358 were excluded from analysis due to violation of inclusion or exclusion criteria, and we report the data on 5,871 (58.5% women) patients who were eligible for analysis. Table 1 summarizes their baseline demographic and clinical characteristics. The mean age of the patients was 66.4 years, including 58.2% at ≥ 65 years old and 22.4% at ≥ 75 years old. The mean LDL-C was 135.9 mg/dL, while total cholesterol was 219.4 mg/dL, high-density lipoprotein cholesterol (HDL-C) was 57.6 mg/dL and the triglyceride (TG) was 122.0 mg/dL (median). Overall, 71.7% of the patients were targeted for LDL-C 120 mg/dL, while 13.3% of patients were not given a target LDL-C. Regarding the atherosclerotic disease risk, the great majority of patients (95.4%) were of older age (men ≥ 45y and women ≥ 55y), and more than 70% of the patients had diabetes mellitus (including impaired glucose tolerance) and/or hypertension, while about 20.9% had a family history of CAD and 20% were smokers. The population included only 11% of patients with low HDL-C ( 40 mg/dL), which reflected the high baseline mean HDL-C. The mean body mass index (BMI) was 24.58 kg/m 2 and 29.0% of the patients were obese ( ≥ 25 kg/m 2 ). Among patients with hypertension, 91% were taking antihypertensive drugs (60% on angiotensin receptor blockers), and 74% of the patients with diabetes (including impaired glucose tolerance) were taking antidiabetic drugs. 
Discussion
This report describes the protocol and patient characteristics for a large-scale Japanese clinical study (APPROACH-J study) of pravastatin that was designed to examine the relationship between LDL-C targets and vascular disease in high-risk patients in primary prevention. Follow-up continued until January 2011 and the main results will be reported in July 2012. The relation between LDL-C levels and cardiovascular disease in a primary prevention population was previously assessed in Japan by subanalysis of the MEGA study. Comparison of the risk of cardiovascular events among quintiles of on-treatment LDL-C showed that the lowest incidence of cardiovascular events was observed in the group with LDL-C ranging from 133.3 to 120.9 mg/dL, but not in the group with the lowest LDL-C, 120.8 mg/dL 14) ; therefore, the relation between LDL-C during statin treatment and events may not necessarily be "the lower, the better", and the possibility of a threshold value has been suggested in primary prevention. Based on these data, the LDL-C target for high-risk patients in primary prevention was set at 120 mg/dL in the JAS guideline 2007, but it remains unknown whether this target level is adequate for patients with a proportionally high-risk profile for atherosclerotic disease, such as diabetes mellitus, hypertension, and so on. The APPROACH-J study included more than 5,000 patients who were categorized as a high risk-population by the JAS guideline, and most of the patients were treated in line with the recommended target LDL-C in the guideline. A large number of patients may maintain 100 to 160 mg/dL LDL-C by pravastatin treatment, expected by the distribution of baseline LDL-C. This indicated that the applicability of the LDL-C target demonstrated in the guideline for high-risk patients in primary prevention can be verified by the relation between the achieved LDL-C and the frequency of vascular disease, such as myocardial infarction and stroke. Moreover, the relation between the risk of events and both the LDL-C achieved and the percent reduction of LDL-C from baseline will be provided, which are considered to be interesting findings.
One of the important goals of this study was to obtain data related to adherence. It is not simply compliance, but is a concept that includes understanding and acceptance of the treatment by the patient, including lifestyle modification 11) . The concept of adherence is included in the most recent 2009 Guidelines on the Treatment of Hypertension 16) . Patients with strong adherence can be expected to show good control of LDL-C, but it is not simply a compliance rate and few data are available on the degree of interest in health among patients or the relation between lifestyle and treatment outcomes. In the present study, we monitored the diet, exercise, smoking, and compliance with drugs including pravastatin and understanding of the medications by the subjects and we plan to investigate the effects of these factors on compliance and achieved serum LDL-C. This study will also assess exercise based on the concepts in the 2006 Exercise and Physical Activity Guide for Health Promotion. A decrease of LDL-C is difficult to achieve even with exercise therapy, but it has been reported that progression of atherosclerosis is inhibited and the risk of cerebrovascular and cardiovascular events is lower in people who exercise regularly compared with those who do not [17] [18] [19] [20] [21] . The results of this survey may provide useful evidence for recommending exercise therapy to patients. The changes that exercise therapy exerts on HDL-C, which is difficult to control with pharmacotherapy, are also of interest.
In this study, LDL-C was measured by both direct and indirect methods in about half of the patients, so it is also possible to examine the correlation between the two methods. From overseas data, it has been found that there is a low correlation between values measured by the direct method and those obtained by the Friedewald formula in persons with high TG values and very low LDL-C values 22, 23) , but it would be very interesting to determine this in a Japanese population. In the present guidelines, the serum LDL-C equivalent to serum TC of 220 mg/dL is 140 mg/dL. We also plan to clarify whether these values are appropriate.
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This study was conducted by Daiichi Sankyo Co., Ltd. as a post-marketing study according to the good post-marketing study practice guideline. All expenses for conducting this study were paid by Daiichi Sankyo Co., Ltd. motor dysfunction, etc.) as symptoms, or functional disorders of the brainstem or cerebellum and medium to large lesions that do not show major contradictions with the patient's symptoms in the cerebral cortex, cerebellum, brainstem, or subcortical regions on MRI/CT, and in whom a cardiac source of embolism could be ruled out, were classified as "atherothrombotic cerebral infarction." b) Cardiogenic cerebral infarction Patients meeting the above stroke criteria, but with one or more source of cardiac embolism, were classified as "cardiogenic cerebral infarction." c) Lacunar infarction Patients with cortical symptoms and normal imaging findings or small lesions with a diameter of less than 1.5 cm matching their symptoms in the brainstem or subcortical areas on MRI/CT were judged to have "lacunar infarction." (6) Cerebral hemorrhage
Patients with hematoma or scarring in the cerebrum, cerebellum, or brainstem on MRI/CT and whose lesions matched their neurological symptoms were classified as having "cerebral hemorrhage;" however, bleeding due to hemorrhagic infarction occurring after cerebral embolism or due to postoperative complications was not included in this classification. (7) Subarachnoid hemorrhage Patients with specific symptoms, such as the sudden onset of headache or vomiting, and hematoma in the subarachnoid space on MRI/CT and/or hematoma confirmed by cerebrospinal fluid examination at lumbar puncture were classified as having "subarachnoid hemorrhage." (8) Arteriosclerosis obliterans Patients corresponding to classes -of the Fontaine classification, who had an ankle-brachial index (ABI) of less than 0.9 or sites of obstruction (stenosis) confirmed by echocardiography, MRA, or angiography, were judged to have "arteriosclerosis obliterans." Even if the details were unclear, if a diagnosis of arteriosclerosis obliterans had been made by another hospital, the case was judged to be arteriosclerosis obliterans.
